Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 8 participants, all of whom received a treatment called ACZ885N (also known as canakinumab). The trial was exploring its use in people with Neuro-Behçet's Disease — a rare condition where Behçet's Disease affects the nervous system. Six of the eight participants completed the trial, and two did not. The trial was described as an exploratory study, meaning it was not designed to draw firm statistical conclusions — it was intended to gather early information rather than definitively test whether the treatment works. The reported data shows the following across several measurements. For the question of how many participants experienced disease attacks (flare-ups) during the study, the number reported was zero — meaning no attacks were recorded among participants during the study period. Of the 8 participants, only 3 were assessed in a neurology clinic and had their neurological function measured using three separate disability scales. On the Modified Expanded Disability Status Scale (a 0–10 scale where higher means more disability), the average reported score for those 3 participants was 1.16. On the Neuro-Behçet's Disability Score (a 0–8 scale, where 8 represents the most severe outcome), the average reported score was 0.66. On the Modified Rankin Scale (a 0–5 scale measuring how much help a person needs day-to-day, where 5 is the worst), the average reported score was also 0.66. One of the 3 neurologically assessed participants was reported to have ataxia (problems with balance and coordination). Muscle strength scores across all four limbs were reported as near-maximum for most limbs assessed, with one limb group averaging 4.7 out of 5. It is important to note that because only 8 people took part — and some measures were only recorded for 3 of them — the reported data is very limited in scope. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 60 years old and have been diagnosed with Behçet's Disease using recognised international diagnostic criteria
- You have recently had a worsening (flare-up) of Behçet's Disease affecting either large blood vessels or the brain/nervous system
- For nervous system involvement: You are having a recent worsening of brain or nervous system symptoms (such as weakness on one side, problems with balance, slurred speech, or headache starting within the last month), AND a brain MRI scan shows related changes in specific areas of the brain (brainstem or diencephalic region)
- For blood vessel involvement: You have had a worsening of disease in large arteries or veins within the last month (such as clots in deep veins, major veins, or large arteries), confirmed by a scan (CT, MRI, or ultrasound)
Who may not be able to join:
- You have serious lasting disability from a previous Behçet's attack that means you need help with daily physical or mental tasks
- Your symptoms are caused by another neurological or vascular condition, not Behçet's Disease
- You have previously been treated with certain biological medicines (other than interferon-alpha) or a medicine called cyclophosphamide
- You have received interferon treatment in the last 6 months, or high-dose steroid infusions in the last month
- You have had any type of skin cancer (squamous cell or basal cell carcinoma) in the past 5 years
- You have, or have previously had, another inflammatory rheumatic disease
- You have a positive tuberculosis (TB) skin test where active TB cannot be ruled out by further testing (confirm with trial site)
- You are currently pregnant or breastfeeding
- You have any active or ongoing infection, or have needed antibiotics given by drip in the last 30 days, or antibiotic tablets in the last 14 days
- You have a history of cancer in the last 5 years (except certain successfully treated skin cancers)
- You are a woman who could become pregnant and are not using the contraception method required by this study
- You have a known allergy or sensitivity to the study drug, canakinumab
- You have taken part in another clinical trial using an investigational drug in the last 30 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Attacks; Modified Expanded Disability Status Scale (EDSS); Neuro-Behçet's Disability Score (NBDS); Modified Ranking Score (mRS); Ataxia; Physical Examination Scores Indicating Change in Muscle Strength; C-reactive Protein (CRP) Values; Erythrocyte Sedimentation Rate (ESR); SAA (Serum Amyloid A); Hemoptysis; Visual Analogue Scores (VAS) for Headache; Visual Analogue Scores (VAS) for Stomachache; Visual Analogue Scores (VAS) for Extremity Assessments; Visual Analogue Scores (VAS) for Patients' General Assessments; Physician's Global Assessment; Steroid Dose Regimen; B...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.